Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024
Friday, July 28, 2023
Larimar Gets FDA Go-Ahead on Phase 2 Friedreich's Ataxia Trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.